Skip to content
Reipet – Lifestyle
Author:
Kyverna Therapeutics, Inc.
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
October 21, 2026
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
October 7, 2026
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
September 24, 2026
Kyverna Therapeutics to Present at Upcoming Investor Conferences
September 2, 2026
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
August 11, 2026
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
July 27, 2026
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
June 22, 2026
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
June 3, 2026
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
May 18, 2026
Kyverna Therapeutics to Present at Upcoming Investor Conferences
May 14, 2026
1
2
Next Page
→